GENUS ONCOLOGY - THE MUC1-C COMPANY
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target

Genus Overview

Genus Overview

Genus Oncology, LLC  (“Genus”) is The MUC1-C Company

MUC1 is aberrantly expressed in most human cancers, including both solid tumors and hematologic malignancies.  Estimates thus indicate that MUC1 is overexpressed in ~900,000 of the newly diagnosed cancers each year in the US.  This prevalence supports why the NCI has ranked MUC1 as one of the most attractive antigen/targets in the fight against cancer.  Despite this attention, there are currently no FDA-approved agents that target MUC1, which was due historically to a limited understanding of how MUC1 functions in causing cancer.

Genus Oncology was formed to advance the seminal work of Professor Donald Kufe at the Dana-Farber Cancer Institute and Harvard Medical School, who has devoted much of his career to understanding MUC1 function and the role it plays in cancer.  Dr. Kufe and the Genus researchers have contributed to the following discoveries that have advanced the MUC1 field:
  • MUC1 is a complex of two subunits (MUC1-N and MUC1-C)
  • MUC1-C is a cancer causing protein.
  • MUC1-C is necessary for growth and survival of carcinoma and leukemia stem-like cells.
  • MUC1-C promotes evasion of cancer cells to immune recognition and destruction
  • MUC1-C is a target for the development of new anti-cancer agents.

Based on these discoveries, Genus Oncology has developed first-in-class peptide-and antibody-based drugs against this novel target.  Our peptide-based drug, GO-203, is currently in a Phase 2 clinical trial in combination with decitabine for patients with relapsed/refractory acute myeloid leukemia (AML) at Harvard’s Beth Israel Deaconess Medical Center and the Dana-Farber Cancer Institute.  Additionally, our antibodies against MUC1-C are being developed for ADC, ADCC, and other immuno-oncology based approaches. 

Company

About Us
Management
Board of Directors
​Contact
​
Sitemap

Science

MUC1-C
Why Target?
MUC1-C in Stem Cells
Publications

Programs

Targeting
Biomarker
Intellectual Property

Pipeline

Pipeline
​Clinical Trials

News

News
​Publications
© COPYRIGHT 2021 ALL RIGHTS RESERVED.
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target